耳念珠菌药敏试验中CLSI、EUCAST、Etest和VITEK®2结果的直接比较。
Head-to-head comparison of CLSI, EUCAST, Etest and VITEK®2 results for Candida auris susceptibility testing.
作者信息
Ceballos-Garzon Andrés, Garcia-Effron Guillermo, Cordoba Susana, Rodriguez Jose Y, Alvarez-Moreno Carlos, Pape Patrice Le, Parra-Giraldo Claudia Marcela, Morales-López Soraya
机构信息
Université de Nantes, Cibles et Médicaments des Infections et du Cancer, IICiMed, EA 1155, F-44000, Nantes, France; Unidad de Proteómica y Micosis Humanas, Grupo de Enfermedades Infecciosas, Departamento de Microbiología, Facultad de Ciencias, Pontificia Universidad Javeriana, Bogotá D.C. 110231, Colombia.
Laboratorio de Micología y Diagnóstico Molecular, Cátedra de Parasitología y Micología, Facultad de Bioquímica y Ciencias Biológicas, Universidad Nacional del Litoral, Consejo Nacional de Investigaciones Científicas y Tecnológicas (CONICET), Santa Fe, Argentina.
出版信息
Int J Antimicrob Agents. 2022 Apr;59(4):106558. doi: 10.1016/j.ijantimicag.2022.106558. Epub 2022 Feb 25.
The susceptibility of 31 Candida auris clinical isolates was evaluated by four methods, namely the microdilution reference method according to Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines as well as Etest and VITEK®2. Essential agreement between the two reference methods was 90%. Etest showed a better overall agreement with the reference methods (94% and 81% for CLSI and EUCAST, respectively) than VITEK®2 (70% and 72%, respectively). Discrepancies were found for fluconazole (FLC) and amphotericin B. Considering categorical agreement (CDC tentative breakpoints), the majority of isolates were considered FLC-resistant (93.6% and 80.6% by CLSI and EUCAST, respectively). Furthermore, all isolates were considered susceptible to echinocandins by all methods. Susceptibility results should be interpreted with care if the VITEK®2 system is used to guide therapeutic decisions for C. auris infections.
采用四种方法评估了31株耳道假丝酵母菌临床分离株的药敏情况，这四种方法分别是根据临床和实验室标准协会（CLSI）及欧洲抗菌药物敏感性试验委员会（EUCAST）指南的微量稀释参考方法，以及Etest和VITEK®2。两种参考方法之间的基本一致性为90%。与参考方法相比，Etest总体一致性更好（CLSI和EUCAST分别为94%和81%），而VITEK®2则分别为70%和72%。在氟康唑（FLC）和两性霉素B方面发现了差异。考虑到分类一致性（CDC暂定断点），大多数分离株被认为对FLC耐药（CLSI和EUCAST分别为93.6%和80.6%）。此外，所有方法均表明所有分离株对棘白菌素敏感。如果使用VITEK®2系统指导耳道假丝酵母菌感染的治疗决策，药敏结果的解释应谨慎。
Zotero 插件